Patents by Inventor Robert J. Hariri

Robert J. Hariri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9925221
    Abstract: Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of ALS.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 27, 2018
    Assignee: Celularity, Inc.
    Inventors: Robert J. Hariri, Jodi P. Gurney
  • Publication number: 20180071343
    Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 15, 2018
    Applicant: Celularity, Inc.
    Inventors: Stewart Abbot, James Edinger, Aleksander Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
  • Publication number: 20170290862
    Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
    Type: Application
    Filed: November 28, 2016
    Publication date: October 12, 2017
    Applicant: Anthrogenesis
    Inventor: Robert J. HARIRI
  • Patent number: 9763983
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 19, 2017
    Assignee: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
  • Publication number: 20170224739
    Abstract: The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20170128625
    Abstract: Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same.
    Type: Application
    Filed: June 15, 2016
    Publication date: May 11, 2017
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Mohit B. Bhatia, Robert J. Hariri, Wolfgang Hofgartner, Jia-Lun Wang, Qian Ye
  • Publication number: 20170080032
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 23, 2017
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20170056452
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Application
    Filed: April 7, 2016
    Publication date: March 2, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Patent number: 9575054
    Abstract: Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 21, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohit B. Bhatia, Qian Ye
  • Publication number: 20170042944
    Abstract: Provided herein are compositions and methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants umbilical cord blood or cells obtained from umbilical cord blood and, optionally, cells obtained from placental perfusate, placental stem cells and/or blood additives. Also provided herein are methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants cells obtained from placental perfusate alone or placental stem cells alone or in combination with umbilical cord blood or cells obtained from umbilical cord blood.
    Type: Application
    Filed: April 20, 2015
    Publication date: February 16, 2017
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Jodi P. GURNEY, Xiaokui ZHANG, Stacy Herb, Cindy HARTUNG
  • Publication number: 20170007648
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 12, 2017
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Patent number: 9539288
    Abstract: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 10, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: Casper Paludan, James W. Edinger, Ryhor Harbacheuski, RoseAnn Murray, Robert J. Hariri
  • Publication number: 20170000779
    Abstract: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.
    Type: Application
    Filed: February 8, 2016
    Publication date: January 5, 2017
    Applicants: Anthrogenesis Corporation, Celgene Corporation, Signal Pharmaceuticals
    Inventors: Robert J. Hariri, David Stirling, Laure A. Moutouh-De Parseval, Kyle W.H. Chan
  • Publication number: 20170002322
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: September 12, 2016
    Publication date: January 5, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20160354433
    Abstract: Embodiments of the present invention are generally related to genetically modified microorganisms. More specifically, embodiments of the present invention relate to genetically modified microorganisms having the avian follistatin genome engineered therein to create a microorganism strain having the enhanced properties of follistatin. In accordance with one embodiment of the present invention, a method of treating an individual with a muscle degenerative disease comprises administering an effective amount of avian follistatin, wherein the avian follistatin is derived from a genetically modified microorganism.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 8, 2016
    Inventor: Robert J. Hariri
  • Publication number: 20160354408
    Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.
    Type: Application
    Filed: February 10, 2015
    Publication date: December 8, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE
  • Publication number: 20160354432
    Abstract: Embodiments of the present invention are generally related to genetically modified microorganisms. More specifically, embodiments of the present invention relate to genetically modified microorganisms having the avian follistatin genome engineered therein to create a microorganism strain having the enhanced properties of follistatin. In accordance with one embodiment of the present invention, a method of treating an individual with a muscle degenerative disease comprises administering an effective amount of avian follistatin, wherein the avian follistatin is derived from a genetically modified microorganism.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 8, 2016
    Inventor: Robert J. HARIRI
  • Publication number: 20160346333
    Abstract: The present invention relates, in part, to the use of stem cells, such as placental-derived stem cells (PDSC), to reduce the effects of aging by, for example, restoring the regenerative engine and extending the lifespan of aging subjects. Provided herein, for example, are methods for maintaining or increasing the ratio of the number of stem cells to the number of differentiated cells in a tissue of a subject over time, comprising administering to the subject an effective amount of a population of stem cells (e.g., PDSC), wherein the ratio is maintained or increased over time as compared to the ratio of the number of stem cells to the number of differentiated cells in a tissue of a control subject over time. Further provided are methods of maintaining or increasing the number of stem cells in a tissue of a subject over time, comprising administering to the subject an effective amount of a population of stem cells (e.g.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventor: Robert J. Hariri
  • Publication number: 20160304832
    Abstract: Provided herein are methods of culturing cells using microcarriers that include extracellular matrix (ECM).
    Type: Application
    Filed: June 23, 2014
    Publication date: October 20, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. HARIRI, Mohit BHATIA
  • Patent number: 9464274
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang